New Research in JNCCN Raises Concerns about Clinical Trial Bias from Undisclosed Censoring
National Comprehensive Cancer Network® (NCCN®)In a new study in the December 2021 issue of JNCCN—Journal of the National Comprehensive Cancer Network researchers examined published randomized control trials supporting FDA approval for treatments for solid tumors from January 2015 through December 2019—and found that for 33 out of 81 studies, it was not clear in the publication why or how patients were being censored (i.e. removed from follow-up before experiencing the outcome of interest).